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The tumor immune microenvironment is a main contributor to cancer progression and a promising therapeutic target for
oncology. However, immune microenvironments vary profoundly between patients, and biomarkers for prognosis and
treatment response lack precision. A comprehensive compendium of tumor immune cells is required to pinpoint predictive
cellular states and their spatial localization. We generated a single-cell tumor immune atlas, jointly analyzing published data
sets of >500,000 cells from 217 patients and 13 cancer types, providing the basis for a patient stratification based on immune
cell compositions. Projecting immune cells from external tumors onto the atlas facilitated an automated cell annotation sys-
tem. To enable in situ mapping of immune populations for digital pathology, we applied SPOTlight, combining single-cell
and spatial transcriptomics data and identifying colocalization patterns of immune, stromal, and cancer cells in tumor sec-
tions. We expect the tumor immune cell atlas, together with our versatile toolbox for precision oncology, to advance cur-
rently applied stratification approaches for prognosis and immunotherapy.
[Supplemental material is available for this article.]
Single-cell RNA sequencing (scRNA-seq) techniques are powerful
tools for the unbiased charting of cellular phenotypes (Lafzi
et al. 2018). Analyzing transcriptome profiles of individual cells
enables the fine-grained annotation of cell types and cellular
states, as well as charting the composition of complex samples.
Interrogating healthy tissues at single-cell resolution provides a
reference atlas of normal tissue organization (Regev et al. 2017)
and defines variability across individuals (van der Wijst et al.
2018) or during development (Asp et al. 2019; Popescu et al.
2019; Park et al. 2020) and aging (Salzer et al. 2018; The Tabula
Muris Consortium 2020). Diseased tissues display an additional
layer of complexity, presenting cell type composition shifts and
newly emerging disease-specific phenotypes (Ramachandran
et al. 2019; Vieira Braga et al. 2019; Chua et al. 2020). In cancer,
in addition to diverse neoplastic cell states (Patel et al. 2014;
Tirosh et al. 2016b), the remodeling of the host tissue microenvi-
ronment has been characterized using scRNA-seq (Tirosh et al.
2016a; Puramet al. 2017). Phenotyping single cells from the tumor
microenvironment (TME) has led to the identification of cancer-
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specific stromal cell states and supported their contribution to
tumor progression. Functional and integrative analysis further
support dependencies of stromal and cancer cells and their predic-
tive value for patient outcome. In particular, cancer-associated fi-
broblasts (CAFs) (Merlos-Suárez et al. 2011; Calon et al. 2015)
and tumor-resident immune cells (Fridman et al. 2012; Yofe et al.
2020) have been identified as biomarkers for patient stratification
and, importantly, as an effective target for therapeutic interven-
tion in oncology (Tumeh et al. 2014; Tauriello et al. 2018).
Clinically most advanced, immune cells are now the target of im-
munotherapy (e.g., immune checkpoint inhibitors, ICI), stimulat-
ing the immune system to recognize and destroy cancer cells.
Single-cell transcriptomics has critically advanced our under-
standing of immune cell diversity in the TME by generating high-
resolution landscapes of different cancer types. Combined with T
cell receptor (TCR) genotyping and receptor-ligand screening
(Mimitou et al. 2019), scRNA-seq identified transient immune
cell states and dynamic tissue remodelling. Seminal studies in-
clude the scRNA-seq-based immunophenotyping of breast cancer,
describing a tumor-specific heterogeneity and expansion of T cell
states, supporting a continuous cell activation toward terminal ex-
haustion, rather than discrete cellular states (Azizi et al. 2018). In
melanoma, similar dynamics were shown to activate transitional
and dysfunctional T cell states (Li et al. 2019). Moreover, single-
cell immunophenotyping identified tumor-specific T cell states,
which are predictive for ICI-based therapy outcome (Sade-
Feldman et al. 2018). A lung cancer study identified an immune ac-
tivation module characterized through high frequencies of
PDCD1+ CXCL13+ activated T cells, IgG+ plasma cells, and SPP1+
macrophages, introducing the concept of an immune cell compo-
sition-based patient stratification to complement current genomic
(e.g., mutational load) or biomarker (e.g., CD274 or CTLA4) strat-
egies (Leader et al. 2020).
Inmore general terms, single-cell sequencing-based immuno-
phenotyping identified cancer-specific states and composition bi-
ases across all major immune cell types that colocalize with cancer
cells (Qian et al. 2020). Major alterations have been described for T
cells (Yost et al. 2019), B cells (Helmink et al. 2020), tumor-associ-
ated macrophages (TAMs) (Lee et al. 2020), and dendritic cells
(Lavin et al. 2017), suggesting a global perturbation of the immune
system in cancer. Comprehensively understanding the causes and
consequences of perturbed immune cell function across cancer
types could provide the basis to identify novel therapeutic targets
and could lay the groundwork for an immune-based patient strat-
ification in precision oncology. Current ICI stratification strategies
involve the assessment of the tumormutational burden or inflam-
mation signatures. However, despite having favorable immune
profiles, many tumors do not respond to treatment, suggesting ad-
ditional mechanisms that confer resistance to therapy. In this re-
gard, the spatial distribution of immune cells has proven to be
important for ICI response, with excluded tumors blocking effec-
tive immune cell action, despite the presence of favorable cell
types at their boundaries (Chen and Mellman 2017). In contrast,
tumors invaded by reactive immune cells that clonally expand
have shown increased response rates. However, current spatial im-
mune profiling approaches enable only targeted profiling of
mRNAs or proteins. On the other hand, the latest spatial transcrip-
tomics (ST) techniques (Ståhl et al. 2016; Rodriques et al. 2019)
provide unbiased transcriptome-wide profiles but average gene ex-
pression profiles of multiple cells.
More broadly, it remains challenging to generalize findings
across cancer types. There are no standardized analysis pipelines
and annotation systems, resulting in data sets characterized by
varying granularity and nomenclature. Cell annotation is especial-
ly challenging when describing novel phenotypes (e.g., cancer-
specific cell states), leading to discrepancies in cell labels between
studies. In this work, we generate a consensus atlas of the tumor
immune microenvironment through the integration of published
scRNA-seq data sets from 13 cancer types for a harmonized and au-
tomated cell annotation, as an input for patient stratification and
to spatially localize immune cell populations in tumor sections.
Results
Generating a tumor immune cell atlas
Single-cell transcriptome profiling of tumors provides an unbiased
overview of the heterogeneity of cancer cells and their microenvi-
ronment. Following sample dissociation, single cells enter scRNA-
seqprocesses either directly or following the enrichment of specific
cell types (e.g., tumor or PTPRC+ immune cells). To generate a com-
prehensive tumor immune cell atlas of human cancers, we collect-
ed scRNA-seq data sets from13different cancer types, 217 patients,
and 526,261 cells. In detail, we processed data from breast carcino-
mas (BC) (Azizi et al. 2018), basal cell and squamous cell carcino-
mas (BCC) (Yost et al. 2019), endometrial adeno- (EA) and renal
cell carcinomas (RCC) (Wu et al. 2020), intrahepatic cholangio-
(ICC) and hepatocellular carcinomas (HCC) (Ma et al. 2019; Zhang
et al. 2019), colorectal cancers (CRC) (Lee et al. 2020; Wu et al.
2020), pancreatic ductal adenocarcinomas (PDAC) (Peng et al.
2019), ovarian cancers (OC) (Schelker et al. 2017), non-small-cell
lung cancers (NSCLC) (Lavin et al. 2017; Lambrechts et al. 2018;
Wu et al. 2020), and cutaneous (CM) and uveal (UM) melanomas
(Supplemental Table 1; Fig. 1A; Sade-Feldman et al. 2018; Li et al.
2019; Durante et al. 2020). For a cell type stratification and consis-
tent annotation, the data sets were analyzed separately before join-
ing immune cells into a pan-cancer tumor immune reference atlas
(Supplemental Figs. 1, 2). In line with previous findings, immune
cells clustered by cell identity rather than patient origin, allowing
the straightforward subsetting of the immune compartment.
We hypothesize that joining cells from different cancer types
into a single reference data set may define commonalities and har-
monize annotations between studies. To this end, we integrated
317,111 immune cells using canonical correlation analysis (Fig.
1B; Butler et al. 2018). This approach identifies common cellular
phenotypes and allows merging data sets from different studies
and technologies for joint analyses. Data integration with alterna-
tive tools resulted in comparable results, thoughwith reduced iLISI
integration score (Korsunsky et al. 2019) and data set-specific tech-
nical clusters (Supplemental Fig. 3). Following integration, cells
separated into 25 clusters representing major immune cell types,
including 12 T cell, five macrophage/monocyte, three dendritic
cell (DC), three B- and plasma B cell, one natural killer (NK), and
one Mast cell cluster (Fig. 1B,C). To test the robustness of the clus-
ters and their associated signatures, we trained a random forest (RF)
classifier to predict cell annotation based on the 25 signatures and
performed a fivefold cross-validation to assess biases and variance.
The mean accuracy and kappa statistic across folds were 0.76 (sd=
0.0048) and 0.75 (sd=0.0050), respectively, a 3.0-fold and 4.2-fold
increase with respect to random signatures and comparable to val-
ues obtained in other high-quality atlases (Supplemental Fig. 4A,B;
Zeisel et al. 2018). In addition, both the interquartile range (IQR)
and the range of accuracies were lower whenusing cell type–specif-










Figure 1. Characterization of the tumor immune cell atlas. (A) Number of cells (top) and patients (bottom) per cancer type included in the atlas. (B) UMAP
of 317,111 immune cells from 13 cancer types colored by annotated cell type. (C) Total number of cells of each immune cell type/state; color code as in A.
(D)Marker gene expression levels for broader cell types (left) and only T cells states (right); color code as in A. (E) Cancer type proportions for each annotated
cell type/state. (F ) Number of unique patients representing each cell type/state in the atlas. (G) Expression of the top four differentially expressed genes per
cell type/state; colored by cell type (as in A) and cancer type (as in E).
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stratifying the accuracies by cell type revealed that the low degree
ofmisclassification corresponded to cell types within the same lin-
eage, which share several markers (Supplemental Fig. 4C). Taken
together this suggests that the clustering of the atlas displays an
optimal balance between granularity and robustness. Of note,
deeper clustering (31 clusters) resulted in a more fine-grained an-
notation of mainly the B cells, with subpopulations representing
naive, activated, memory, unswitched memory, and proliferative
subtypes (Supplemental Fig. 5).
Clusters were manually annotated using canonical markers
and curated gene signatures that defined their identities (Supple-
mental Tables 2, 3). Exemplarily, CD4 T cells representing regula-
tory, helper, andnaive states were defined by FOXP3,CXCL13, and
SELL marker gene expression, respectively (Fig. 1D; Supplemental
Fig. 6). Cytotoxic CD8 T cells expressed high levels of GZMA,
whereas their pre- and terminally exhausted subtypes expressed
IFIT3 and HAVCR2, respectively. Macrophages split in different
subtypes, such as C1QC, SPP1, and pro-inflammatory states,
with C1QC, SPP1, and CXCL8 as respective marker genes. We fur-
ther observed actively dividing lymphoid and myeloid cell types
withMKI67 and STMN1 as commonmarkers for proliferation. Plas-
ma B cells specifically expressed IGKC, which distinguished them
from naive/memory B cells expressing MS4A1. The large number
of immune cells enabled the identification of rare cell states,
such as proliferative B cells (834 cells) and macrophages (1048
cells) as well as plasmacytoid and conventional DC populations
(2140 and 2238) (Fig. 1C). All cell types were present in multiple
cancer types and patients (Fig. 1E,F), which supports the robust-
ness of the integration approach. Our analyses revealed that sever-
al cell states such as naive, proliferative, transitional memory and
terminally exhausted T cell subtypes, and all macrophage states
were abundant in all tumors, highlighting common mechanisms
that operate in the TME independently of the tissue of origin
andmutational background. Yet, we also found cell states enriched
in specific cancer types, suggesting cancer-specific immune envi-
ronments (Fig. 1E). In particular, effector memory CD8 T cells
were frequently found in EA and NSCLC, proliferating B cells
were very abundant in PDAC, whereas Mast cells were mainly de-
tected in BC. In summary, we built a catalog of immune cell types
and statemarkers present in the TME ofmultiple cancer types (Fig.
1G; Supplemental Table 4). This resourcemayhelp annotate future
single-cell tumor data sets.
Tumor stratification by immune cell composition
Tumors of the same cancer type have been described to be hetero-
geneous, presenting distinct genetic and epigenetic alterations as
well as gene expression signatures, allowing their stratification
into subtypes. Cancer subtypes have a clear impact on clinical
management, being predictive for patient prognosis and therapy
response (e.g., consensus molecular subtypes in CRC [CMS])
(Guinney et al. 2015). To date, gene expression subtypes are de-
fined through the analysis of bulk tumor samples and are frequent-
ly characterized by gene signatures of stromal or immune cell types
(Calon et al. 2015). Single-cell resolved tumormaps confirmed this
contribution of the TME to the subtype classification and allowed
an even more fine-grained interpretation of subtype composition
(Lee et al. 2020).
Detecting varying immune cell compositions within cancer
types but conserved profiles across cancers, we sought to establish
a pan-cancer immune classification system. We used immune cell
type and state frequencies of the reference atlas as input for simi-
larity assessment across the 13 cancer types (Fig. 2A). Samples of
different tumor types intermixed, and cancer type was not a
main source of variance as shown in a t-distributed stochastic
neighbor embedding (t-SNE) of immune cell type proportions
(Fig. 2B). In contrast, abundance of CD4 effector memory T cells
explained most variance in the data set (principal component 1,
43.7%), followed by the relative frequencies of C1QC TAMs and
terminally exhausted CD8 T cells (32.6% and 9.5%, respectively)
(Fig. 2C).
Correlating immune cell population frequencies identified an
intriguing pattern of tumors beingmutually exclusive for the pres-
ence of lymphoid or myeloid cell types (Supplemental Figs. 7, 8A).
Moreover, lymphoid-enriched tumors presented either naive-
memory, effector-memory and recently activated profiles, or
more differentiated (regulatory, cytotoxic, and exhausted) pheno-
types.Myeloid-enriched tumors further split into pro-inflammato-
ry and inhibitory (C1QC and SPP1 TAMs) subtypes, the former
correlating with the presence of plasmacytoid and myeloid DCs.
A hierarchical k-means clustering using immune cell proportions
as features defined six clusters with largely different compositions
(Fig. 2A,B,D,E). In spite of the different sizes of the clusters, almost
all cancer types were presented in each cluster, confirming large
commonalities of immune cell compositions between them (Fig.
2F). Tumors in cluster 1 (C1) showed a high proportion of recently
activated and naive-memory CD4 T cells, whereas C2 had high
amounts of cytotoxic and terminally exhausted CD8 cells (Fig.
2D,E). C3 displayed exceptionally high levels of macrophages
(C1QC and SPP1), C4 was driven by increased frequencies of plas-
ma B cells, C5 contained high proportions of CD4 effector memo-
ry T cells, and C6 was very high in B cells. To confirm the
proportional differences of cell types between clusters, we applied
scCODA, confirming the enrichment of cluster-specific cell states
and the largely mutually exclusive distribution of myeloid and
lymphoid cell types in tumors (Supplemental Fig. 7). The cell-
type enrichmentwas further confirmed by generalized linearmod-
els interrogating the differences in cell abundance across experi-
mental conditions and cancer types, also accounting for batch
effects. We observed the cluster-defining cell types to be statisti-
cally enrichedwithin their respective clusters (Supplemental Table
5). Consistent with the distinct cell type proportions, the clusters
presented specific gene expression signatures (Supplemental Fig.
8B; Supplemental Table 6). Intriguing from a therapeutic perspec-
tive, C5 showed a striking increase of exhaustion markers on CD8
cells with significantly higher levels of LAG3, PDCD1, and CTLA4
(ANOVA, P<0.01) (Supplemental Fig. 8C,D). The fact that these
markers are also target for immune-therapy suggests C5 tumors
to be more susceptible to ICI treatment but could also shed light
on the role of CD4 effector memory cells, strongly enriched in
these patients (Fig. 2D,E). In line with this, the presence of specific
immune cell states, such as regulatory T cells or anti-inflammatory
TAMs, has been linked to immune-therapy efficacy. Thus, it is
tempting to speculate that the here-identified patient clusters dif-
fer in their response to ICIs.
To facilitate the classification of immune profiles of future
data sets, we trained a RF classifier with the 25 immune cell popu-
lation achieving a highly accurate classification (accuracy: 0.8,
95% CI: [0.593, 0.932]; P-value: 5.36×10−5) (Supplemental Meth-
ods). Of note, the cluster-specific cell types were also the most im-
portant variables when training the RF classifier using cell type
proportions as features to predict cluster identities (Supplemental
Fig. 9). To integrate our patient clusters with large clinical RNA se-
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cell derived clusters (Fig. 2C) to deconvolute bulk RNA sequencing
data sets from the Tumor Cancer Genome Atlas (TCGA) program.
Specifically, we inferred tumor immune cell proportions for 1222
breast invasive carcinoma (BRCA), 594 lung adenocarcinoma
(LUAD), 472 skin cutaneousmelanoma (SKCM), and 521 colon ad-
enocarcinoma (COAD) samples. Following deconvolution, we ap-
plied the aforementioned RF classifier to assign TCGA samples to






Figure 2. Patient stratification based on the tumor immune cell composition. (A) Cell type composition of patients colored by cell type/state frequencies.
Patients are clustered (C1–6) into groups of similar cell type composition. Cancer and cluster identities are indicated below. (B) Dimensionality reduction
representation (t-SNE distribution) of cell type frequencies in cancer patients colored by cancer type (top) and cluster identity (bottom). (C) Variance con-
tribution to the two first principal components (PCs) of the top variable cell types. (D) Frequencies (% total cells) of cell types representative for cluster 1–6.
(E) Heat map representation of cell type frequencies within each cluster. (F) Cancer type contribution to the six immune clusters; color code as cancer
types in A.
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could assign patients from all cancer types to the single-cell de-
rived clusters, with the exception of our smallest cluster enriched
in plasma B cells (Supplemental Fig. 10).
A resource for immune cell annotation
To demonstrate the predictive value of the atlas, we generated que-
ry data sets from different cancer types and varying experimental
designs. Following clustering of the query data sets, we projected
either single cells or clusters onto the atlas using a reference-based
projection (Butler et al. 2018) or cluster matching (Mereu et al.
2020) tools, respectively. As proof-of-concept, we performed
scRNA-seq for human primary OC and UM, liver metastases
(from primary UM), as well as a brain metastasis (from primary
CM).
Using cell-by-cell projection, wematched UM andOC cells to
specific cell types and states of the atlas reference (Fig. 3A,D).
Query cells projected to macrophage and T cells, with a large vari-
ety of cell states being detected. The UM harbored all macrophage
subtypes, including abundant SPP1 and C1QC TAMs and a small
fraction of proliferativemacrophages (Fig. 3A). In addition, the en-
tire spectrum of T cell phenotypes could be assigned, with a high
fraction of cells projecting to the terminally exhausted CD8 T
cell state. The OC data set contained less SPP1 TAMs and exhibited
an increased proportion of proliferativemacrophages (Fig. 3D).We
also detected a small number of conventional DC andmonocytes.
We next used clustering analyses on the query data sets and subse-
quently matched the identified clusters to the atlas reference.
There were seven and three clusters for UM and OC, respectively
(Fig. 3B,E).Matching the query and reference atlas clusters resulted
in a clear separation between the lymphoid and myeloid popula-
tions (Fig. 3C,F). In UM, cytotoxic and terminally exhausted cells
were enriched in cluster 1 and cluster 6, in line with their distribu-
tion in the dimensionality reduction representation (Fig. 3A). SPP1
TAMs showed higher scores in cluster 2, whereas C1QC TAMs fell
into cluster 4, an assignment consistent with the cell-by-cell pro-
jection. Cluster 7 matched to both lineages, likely depicting cell
doublets.
The projection of cells from UM liver metastases rendered a
precise separation of T cell states (Fig. 3G), which split into naive,
recently activated, cytotoxic, and proliferative subpopulations.We
found a distinct frequency of exhausted cells between both UM
metastases. Althoughmuch less abundant, all DC and B cell states
could also be assigned in both samples. Cell-by-cell projection of T
cells fromaNSCLCbrainmetastasis also identifiedmost cell states,
with a high proportion of terminally exhausted CD8 T cells (Fig.
3H). Combined scRNA-seq and TCR genotyping assigned clonally
expanded T cells as being either actively proliferating or terminally
exhausted, in line with the expected history of tumor reactivity
and proliferation of exhausted cells (Fig. 3H,I; Azizi et al. 2018;
Li et al. 2019).
We further wondered about the applicability of the atlas as a
reference across species. To tackle this question, we generated
scRNA-seq data sets for two liver metastases derived from mouse
CRC organoids (Tauriello et al. 2018), one PTPRC selected and
the other enriched in T cells, and projected individual cells onto
the human reference. The mouse data sets could be projected
with high confidence (∼70% of cells with matching probabilities
> 0.5).Mouse clusters ofmain subtypes could be readily annotated,
and specific subpopulations could also be assigned to distinct T/B
cell or macrophage cell states using the human reference (Fig. 4A–
D). Again, distinct T cell states emerged from the dimensional re-
duction plots or after clustering analysis (Fig. 4A–C). Consistently,
cell projection of the experimentally enriched T cell fraction to the
reference atlas identified defined T cell states (Fig. 4E). Clonal ex-
pansion according to TCR sequencing could only be detected in
cells assigned to be proliferative, cytotoxic, or exhausted, whereas
naive, naive-memory, and recently activated cells were not of clon-
al origin (Fig. 4E,F).
Spatial localization of immune cells in tumor sections
Widespread evidence indicates that the spatial distribution of im-
mune cells is important for ICI response (Chen and Mellman
2017). To explore this issue, we combine single-cell reference atlas
immune profiles with ST data from tumor sections. The aim of this
approach is to provide spatial tumor maps that precisely delineate
colocalization of immune cells in tumors. To integrate both data
modalities, we applied SPOTlight, a nonnegative matrix factoriza-
tion (NMF)-based spatial deconvolution framework (Elosua-Bayes
et al. 2021). SPOTlight identifies cell type–specific topic profiles
(gene expression signatures) from scRNA-seq data, which are sub-
sequently used to deconvolute ST spots. To predict and quantify
the location of the 25 cell types and states of the tumor immune
reference, gene expression profiles were translated into SPOTlight
topic profiles. Topics were highly specific to clusters, resulting in
high specificities to localize immune cell types (Fig. 5A). To avoid
conflicting signals and inaccurate predictions related to the pres-
ence of strong cell cycle signatures from cancer cells, we removed
proliferating immune cells from the deconvolution step and
included a general proliferation signature to identify areas of divid-
ing cells. Tomap immune cells within tumor sections, we generat-
ed ST data sets for an oropharyngeal squamous cell carcinoma
(SCC) metastasis and analyzed two sequential sections of an inva-
sive ductal BC (Visium platform, 10x Genomics).
Clustering the spatial SCC data identified four distinct tran-
scriptional and proliferative active areas containing cancer cells
(cluster 1/2), surrounded by stroma (cluster 0) and an area enriched
in immune cells (cluster 3) (Fig. 5B–E). Mapping the immune cell
distribution in the sections using SPOTlight returned proportions
for each cell within a spot, predictions that were validated using an
alternative spot deconvolution tool (Supplemental Fig. 11; Cable
et al. 2021). This resulted in a clear regionalization of distinct im-
mune cell types and states (Fig. 5D; Supplemental Fig. 12). The
cancer areas cluster 1/2 presented similar patterns, with an enrich-
ment of the proliferation signature and SPP1macrophages (Fig. 5F,
G; Supplemental Fig. 13). Cluster 3, in turn, presented a specific
immune infiltration pattern dominated by an enriched presence
of B cells and cDCs. The stroma section, cluster 0, harbored regula-
tory T cells and terminally exhausted CD8 T cells and was specifi-
cally enriched in C1QC TAMs. An interaction matrix computed
based on the predicted proportions on the spatial distribution of
cell states in the section highlighted colocalization andmutual ex-
clusive patterns (Fig. 5H; Supplemental Fig. 14). Here, spatial
colocalization provided further insights into immune-modulating
mechanisms of cancer and immune-suppressive stromal cells (e.g.,
regulatory T cells). Exemplarily, recently activated T cells colocal-
izedwith effector/naivememory T cells, whereas theywere exclud-
ed from areas with regulatory and exhausted T cells as well as
C1QC TAMs and plasma B cells. Accordingly, regulatory T cells
showed a positive correlation with cytotoxic cells (including
NK), pre- and terminally exhausted CD8 T cells, and C1QC











Figure 3. Automated annotation of external human tumor-derived immune cells using the tumor immune atlas as reference. (A,B) UMAP representation
of immune cell transcriptomes from a primary uvealmelanoma colored by their predicted cell type/state based on the tumor immune reference (A) or using
unsupervised clustering (B). (C) Marker correspondence (Jaccard index) between uveal melanoma clusters (B) and the cell type clusters of the reference
atlas. (D,E) UMAP representation of immune cell transcriptomes from a primary ovarian carcinoma colored by predicted cell type/state (D, color code
as in A) and after clustering (E). (F ) Marker correspondence (Jaccard index) between the ovarian cancer clusters and the cell type clusters of the reference
atlas. (G) UMAP representation of immune cells from two uveal melanoma liver metastasis colored by their predicted cell type (color code as in A). (H,I)
UMAP representation of T cells isolated from a brain metastasis colored by their predicted cell type (H, color code as in A) and clonal expansion profiled
through TCR genotyping (I).
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effector/naive memory T cells. It has been shown that regulatory T
cells inhibit effector T cells by releasing ENTPD1 (previously
known as CD39) and NT5E (also known as CD73) that bind to
the A2A receptor (Allard et al. 2020). In line with this finding,
and in addition to the exclusive pattern of regulatory and activated
and effector T cells, we detected a positive expression correlation of
ENTPD1 andNT5Ewith the regulatory T cell predicted proportions
(P<2.2 ×10−16 and P=2.5 × 10−6, respectively). Along with the de-
tected spatial organizationwith other immune cell types, regulato-
ry T cells illustrate the value of spatial immune mapping to
advance our understanding of tumor immunology. Analysis of a
second SCC case confirmed the regional restriction of tumor im-
mune cells and confirmed the previously described colocalization
and mutually exclusive patterns (Supplemental Figs. 15–17).
In order to validate the colocalization of abovementioned cell
type and states, we performed a digital in situ hybridization (digital
ISH) experiment by correlating the presence of canonical expres-
sionmarkers of these cells. Although being less sensitive, ST gener-
ates accurate molecule counts, thus returning an adequate signal
for targeted colocalization (same spot) analysis. To enhance the
signal, we denoised the data (van Dijk et al. 2018) before comput-
ing a clustered correlation matrix of marker genes (Supplemental
Fig. 18A). We observed strong correspondence of cell type marker
gene colocalization with the predicted proximity of respective cell
types. Specifically, the localization ofGNLY andNKG7 (cytotoxic T
cells) correlated significantly with FOXP3 andCTLA4 (regulatory T
cells) (Supplemental Fig. 18B–D). On the other hand, the correla-




Figure 4. Projecting mouse tumor immune cells onto the human reference atlas. (A,B) UMAP single-cell transcriptome representations of mouse T cells
isolated from tumor organoids. Cells are color-coded by their predicted cell type based on the human reference atlas (A) or by cluster identity (B). (C ) Cell
type composition of each cluster (color code as in A). (D) Marker gene correspondence (Jaccard index) between the mouse immune clusters and the cell
type clusters of the reference atlas. (E,F ) UMAP representation ofmouse T cells isolated from tumor organoids colored by predicted cell type (E, color code as












Figure 5. Spatial mapping of the reference immune cell types using ST oropharyngeal squamous cell carcinoma (SCC) sections. (A) Cell type–specific
topic profiles presenting a high topic/cell type specificity. (B) ST profiled section of a SCC primary tumor. Tissue stratification according to unsupervised
clustering. (C ) The number of unique molecular identifiers (UMI) recovered from each spot indicate the areas transcriptionally most active. (D) Pie chart
representation showing proportions (per ST spot) of SPOTlight-predicted immune cells based on the single-cell immune reference atlas. To visualize spa-
tially variable cell types, only immune cell types present in <75%of the spots are displayed. (E) UMAP embedding of ST spots presenting the cell cycle phase
(left) and cluster identity (right) for each spot. (F ) Box plots displaying significant differences in cell type proportion of clusters (ANOVA test). (G) Location
and proportion of significantly differentially located cell types in the SCC section. (H) Clustered correlation matrix between the predicted cell type propor-
tions identifying colocalization (red) and exclusive (blue) immune distribution patterns.
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as well as proliferation markers (STMN1,MKI67, CDK1) confirmed
the colocalization of SPP1 TAMs with proliferating cancer cells
(Supplemental Fig. 18E–G). Finally, our digital ISH experiment
confirmed the colocalization of stromal cells (ACTA2, PDGFRA)
with regulatory T cells (FOXP3, CTLA4), terminally exhausted T
cells (PDCD1, LAG3, HAVCR2), and C1QC macrophages (MRC1,
CD163) (Supplemental Fig. 18A).
A cancer-specific regional distribution was also observed in
the invasive ductal BC and replicated over serial sections of the tu-






Figure 6. Tumor immune reference mapping ST section from a ductal breast carcinoma. (A) Pie chart representation showing proportions (per ST spot)
of SPOTlight-predicted immune cells based on the single-cell immune reference atlas. To visualize spatially variable cell types, only immune cell types pre-
sent in <75% of the spots are displayed. (B,C) Estrogen receptor 1 (ESR1, B) and erb-b2 receptor tyrosine kinase 2 (ERBB2, also known as HER2, C) gene
expression levels on the ST section, indicating profound regionality of the expression. (D) Tissue stratification and labeling according to unsupervised clus-
tering. (E) Box plots of significantly differentially localized cell type proportions between the clusters (ANOVA test). Differences between tumor areas (i.e.,
HER2+ and ESR1+) are observed, suggesting differential tumor microenvironments of the tumor subclones. (F) Location and proportion of immune cell
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profiles of cancer cells pointed to a strong subclonal structure, with
mutually exclusive localizations of BC subtype-specific ERBB2
(HER2+) and ESR1 (ESR1+) positive clones. This subclonal architec-
ture was directly associated with local enrichment of distinct cell
states (Fig. 6D; Supplemental Figs. 20, 21). The ESR1+/HER2−
region showed the increased presence of proliferating cells and
SPP1 macrophages (Fig. 6E,F; Supplemental Figs. 22, 23). In con-
trast, the HER2+/ESR1− region showed a higher proportion of reg-
ulatory and cytotoxic T cells, C1QC TAMs, and NK cells. In this
region, coupled to the higher proportion of regulatory T cells, we
also observed an enrichment of pre-exhausted and terminally ex-
hausted CD8 T cells, different inactivation stages of the immune
cell response. Lastly, we observed an enrichment of plasma B cells
and C1QC TAMs lining the cancer areas in the fibrotic tissue. The
importance of a quantitative assessment of cell types within ST
spots is displayed by the ubiquitous presence of SPP1macrophages
across all areas but the significant proportional enrichment in spe-
cific tumor fractions (Fig. 6E,F). Similar to the SCC, spatial correla-
tion analysis in BC, among other features, identified the
colocalization of proliferating cells and SPP1 macrophages along
with the anticorrelation with regulatory and cytotoxic cells and
C1QC TAMs (Supplemental Fig. 14B,C).
Discussion
We jointly analyzed 317,111 immune cells from 217 patients, in-
cludingmajor (e.g., T cells, B cells, andmacrophages) and rare (e.g.,
proliferating and dendritic cells) cell types and states infiltrating
human tumors. We stratified cell types into subpopulations and
annotated a fine-grained map of immune cell states. We envision
this atlas to serve as a reference for a harmonized annotation of
future data sets, whichwe tested by projecting single cells frompri-
mary human tumors and metastases as well as mouse immuno-
therapy models onto the atlas. The here-identified 25 cell types/
states present a compendium of immune cell populations shared
across cancer types to enable personalized medicine applications.
Whereas the RF classifier pointed to the robustness of the clusters,
increasing the cluster number could identify additional biological
relevant and functional cell states. This was exemplified by the
identification of additional B cell states through deeper clustering,
and we expect the large cell number of this atlas to allow an even
deeper annotation.
Observing high cell state heterogeneity across patients and
cancer types enabled a patient stratification based on the immune
composition. This immune-based classification identified pan-
cancer subtypes exclusively enriched in recently activated CD4 T
cells, cytotoxic/terminally exhausted CD8 T cells, CD4 effector
memory, C1QC tumor-associated macrophages, or B cells and
plasma B cells. We believe pan-cancer immune classifications to
be highly informative and clinically predictive when integrating
tumor samples from single-cell studies with patient survival and
response to therapy metadata. We thus envision our immune-
based patient classifier to be a useful tool for future patient stratifi-
cation, predicting prognosis and immunotherapy response.
Moreover, using the classifier, the pan-cancer immune classifica-
tion system could be extended to additional cancer types and drive
the design of basket clinical trials in which a common immune
stratification and recruitment framework is applied across cancer
types.
Detecting regional immune cell enrichments in tumor
clones and adjacent areas, we foresee an application of the atlas
in digital pathology to guide immunotherapy decisions. The tu-
mor immune cell reference, in combination with SPOTlight-
based spatial mapping of ST data, enables harmonization of the
spatial assessment of tumor infiltrating immune cells, a first
step toward an automated digital pathology framework. We fore-
see the regional distribution of immune cell types becoming an
important feature for the prediction of immunotherapy outcome.
Moreover, longitudinal sampling for spatial immune cell map-
ping throughout ICI treatment could aid in explaining therapy
action and point to further weaknesses approachable through
combinatorial therapy strategies. However, it is of note that pre-
dicting the presence of immune cell types from a reference atlas
cannot comprehensively take into account cell type– or patient-
specific peculiarities. Overlapping gene expression signatures, as
shown for the proliferation-related transcriptional program, can
challenge distinguishing the presence of immune cells from cell
types that are not present in the training set. Consequently, ad-
ditional analysis, such as the here-applied digital ISH validation,
or experimental validation should be considered.
In conclusion, our analysis allowed us to catalog tumor-resi-
dent immune cells across a large patient cohort and to draw a com-
prehensive tumor immune cell atlas of human cancers. We
envision the application of the atlas in multiple areas of precision
oncology. Therefore, we provide a framework for an immune-
based patient stratification, the feasibility to integrate newly gen-
erated patient single-cell data, and a toolbox to map immune cells
directly in tumor sections. Following the integration of clinical co-
hort single-cell studies with patient outcome and response meta-
data, we expect the atlas to be predictive for patient prognosis
and immunotherapy response to a level that greatly exceeds cur-
rently applied stratification strategies.
Methods
Data preprocessing
We initially preprocessed each scRNA-seq data set independently:
breast carcinomas (obtained from the NCBI Gene Expression Om-
nibus [GEO; https://www.ncbi.nlm.nih.gov/geo/] accession num-
bers GSE114727 and GSE114725), basal cell and squamous cell
carcinomas (GEO GSE123814), endometrial adeno- and renal
cell carcinomas (GEO GSE99254), intrahepatic cholangio- and
hepatocellular carcinomas (GEO GSE125449, GSE140228), colo-
rectal cancers (GEO GSE132465, GSE99254), pancreatic ductal
adenocarcinomas (Genome Sequence Archive [GSA; https://ngdc
.cncb.ac.cn/gsa/] accession number CRA001160), ovarian can-
cers (https://figshare.com/s/711d3fb2bd3288c8483a), non-small-
cell lung cancers (ArrayExpress [https://www.ebi.ac.uk/array
express] accession numbers E-MTAB-6149, E-MTAB-6653 and
GEO GSE97168, GSE99254), and cutaneous (GEO GSE120575,
GSE123139) and uveal (GEO GSE139829) melanomas.
From the original count matrices, we filtered the low-quality
cells based on mitochondrial RNA percentage, number of UMIs
(unique molecular identifiers), and number of different genes
(thresholds adjusted separately for each data set). Then, we ob-
tained the highly variable genes, corrected, logarithmically nor-
malized, and scaled the counts (default parameters) of each data
set using Seurat (version 3.2.0) (Stuart et al. 2019). Principal com-
ponent analysis (PCA) was performed on all individual data sets.
The optimal number of principal components ranged between
25 and 40, depending on data set size. Dimensionality reduction
was performed by applying the UniformManifold Approximation
and Projection (UMAP) algorithm, which also served as a two-di-
mensional embedding for data visualization. Cluster analysis was
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performed using the Louvain clustering algorithm, a method sep-
arating different communities inside the data by optimizing the
modularity measure. The clusters were annotated by expression
of canonical markers of major cell types to consistently identify
and extract immune cells. Before data set integration, the major
cell types were identified, that is, T, B, myeloid, and dendritic cells,
and separated from the tumor cells. Note that, for some data sets,
prior information for cell-level annotation was also available.
Tumor immune cell atlas construction
To construct the atlas, we used the raw counts from the previously
annotated immune cells of each data set and followed Seurat’s
standard data integration pipeline. This method is based on the
identification of anchor cells between pairs of data sets, which
are used to harmonize the integrated data sets. To do this, canon-
ical correlation analysis (CCA) is applied, for which we set the
number of anchors to 3000. Prior to integration, we obtained the
data set-specific genes in order to remove them from the integra-
tion anchors, thereby reducing noise. To do this, we joined all
the data sets and, with the FindAllMarkers function, calculated
the genes specific for each data set. Then, we removed these genes
from the integration features.
Integrating multiple data sets is a computationally intensive
procedure. Due to the large number of atlas cells, we used the alter-
native reciprocal PCA (RPCA) algorithm for anchor identification,
as proposed by Stuart et al. (2019). This method is notably faster
and performs considerably similarly to the standard CCAmethod.
With this procedure, we built a tumor immune cell atlas of over
300,000 immune cells across 13 cancer types and 217 patients.
After integration, we computed the clusters again to obtain a
fine-grained resolution of cell types and states. We increased the
resolution parameter in Seurat’s FindClusters up to 1.2, to retain
more subtle differences between subpopulations.
We performed differential expression analysis (DEA) for all
clusters to determine their marker genes. For the DEA, we used
the normalized RNA counts, instead of using the integrated data,
to increase the accuracy identifying significant cluster makers.
To further refine the cluster signatures, we computed the clusters
using both the Wilcoxon rank-sum test and MAST (Finak et al.
2015) methods and kept only genes identified with both ap-
proaches. We annotated the refined clusters using a curated gene
signature of immune cell subtypes and compared it with the re-
sults of the DEA analysis (using the matchSCore package [Mereu
et al. 2020]). Here, not only the major immune cell types but
also different immune cell states were identified.
Clustering and classification of patients based on immune
cell composition
In order to find similarities in patients’ immune microenviron-
ment across cancer types, we applied patient clustering using the
proportion of 25 immune cell states of their TME. For this, we fil-
tered out patients with less than 500 cells and applied hierarchical
k-means (HKM) clustering (Chen et al. 2005; Alashwal et al. 2019)
using the cell types as variables and their proportion in the TME as
values. We set the number of clusters to k =6 (Supplemental Fig.
9B) and used the agglomerative Ward 2 method with Euclidean
distance metric. This algorithm iteratively joins instances in clus-
ters, reducing intra-cluster variance. Further, we built a RF classifier
to predict the assignment of each patient to one of the six immune
subtype clusters. Therefore, we split the data set into training and
test sets (75% and 25% of the patients, respectively) and grew 100
trees to train the classifier, while automatically assessing predic-
tor’s importance and calculating the proximity between patients
for a better model. To evaluate the variable importance obtained
from the RF classifier, we assessed how the accuracy of the model
decreased when a variable is excluded from the model (mean
decrease accuracy) and how each variable affects the homogeneity
of the trees in the forest (mean decrease Gini). We then used
scCODA to statistically confirm proportional differences in cell
type abundance in the six patient clusters. Therefore, we included
all cell types/states of the atlas, and let the algorithm automatically
select a reference cell type for scCODA’s model (transitional mem-
ory CD4 T cells). Of note, using proliferative T cells as a reference
cell type produced similar results. We then tested each of the clus-
ters against the rest, setting the patient and the cluster as covari-
ates. We used scCODA’s default model and algorithm and
gathered the results of the estimated parameter and log2-fold
change for each of the six contrasts (one per cluster). These results
further confirmed and provided statistical support for the differ-
ences in patient cluster cell type composition (Supplemental Fig.
7). To further assess the robustness of the patient clusters and
to identify significantly enriched cell types, we used generali-
zed linear models (GLMs). Specifically, we used the R package
“emmeans” to perform the contrasts between the clusters and in-
cluded the batch (data set of origin), cancer type, and sequencing
technologies, as covariates of the models (Supplemental Table 6).
Both scCODA and GLM analysis confirm our observations.
Data set projection onto the tumor immune cell atlas
For the projection and annotation of external data sets onto the at-
las, we used Seurat’s anchor-transferring method. This algorithm
uses the PCA structure of the reference atlas and projects it on
the query. Then, it finds pairs of anchor genes between data sets
that enable the projection. These anchors allow the transfer of an-
notations (labels) between data sets. Here, we used an unsuper-
vised anchoring based on the first 30 principal components of
the data sets and the RNA assays with a LogNormalize normaliza-
tion method.We obtained the cell-type assignment of each cell in
the query data sets plus the corresponding prediction probability.
We also used matchSCore2’s function to correlate the markers of
query clusters with themarkers of the 25 cell types/states of the at-
las. Therefore, we used the top 100markers (average log-fold chan-
ge) for each of the clusters.
Spatial transcriptomics analysis
Clusters were annotated according to pathologists’ assessment,
their transcriptional activity, and differentially expressed genes.
A subset of the single-cell atlas was used to train the SPOTlight
model; we selected up to 100 cells coming frommelanoma cancer
for each cell type/state. Selecting cells from one of the cancer
types allowed us to reduce data set-specific noise, which could con-
found the model. The gene set used to train the model was the
union between the marker genes of the cell types along with the
top 3000 variable genes. Marker genes for each cell type were oba-
tinedwith Seurat’s function FindAllMarkers, considering only pos-
itive markers and setting the logFC and min.pct to 0 to include all
genes. All markers were used to initialize the model basis, and unit
variance normalization was carried out. Nonsmooth, nonnegative
matrix factorization was the method used to carry out the factori-
zation. Cell types contributing <3% to the spot’s predicted compo-
sitionwere considered fitting noise andwere set as 0.We then used
SPOTlight to map the atlas cell types to the spatial spots. For the
digital ISH, we reduced data sparsity and enhanced gene expres-
sion signals withMAGIC (vanDijk et al. 2018), applied on the nor-
malized gene expression data. We ran MAGIC with default
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used to recover the data structure is based on the most similar ST
spots.
Data access
The Tumor Immune Cell Atlas count matrix and metadata
are deposited at Zenodo (https://zenodo.org/record/5186413#
.YRqbJC1h2v6). The analysis code is available at GitHub (https://
github.com/Single-Cell-Genomics-Group-CNAG-CRG/Tumor-Immune-
Cell-Atlas) and as Supplemental Code. Raw data are available as
stated in the Supplemental Methods. To explore the atlas, project
external data, and apply the immune classifier, we are currently
developing a user-friendly ShinyApp accessible at https://paula-
nieto-garcia.shinyapps.io/TICA/. Raw data for the projected sin-
gle-cell and ST data sets generated in this study have been submit-
ted to the NCBI Gene Expression Omnibus (GEO; https://www
.ncbi.nlm.nih.gov/geo/) under accession number GSE158803.
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